Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

计划入组 29 人 · 首次发布于 2018 年 5 月 3 日

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

计划入组 34 人 · 首次发布于 2018 年 10 月 17 日

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

计划入组 103 人 · 首次发布于 2019 年 5 月 30 日

LAGE-1A TCR-T cell therapy(Anocca AB)

NY-ESO-1/LAGE-1A TCR-T cell therapy(Anocca AB)

BC008-1A

Sage Bionetworks

United States

Sage Therapeutics

United States

Cage Bio Inc.

United States

Medigene Advances TCR-T Therapies with FDA Clearance and Strategic Partnerships

FDA Clears IND for Medigene's TCR-T Therapy MDG1015 in Advanced Solid Tumors

Medigene AG Refocuses Strategy on TCR-Guided Therapies, Pauses MDG1015 Trial